Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cytek Biosciences Reports First Quarter 2023 Financial Results
May 9, 2023 4:05 PM EDTFREMONT, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2023.
First Quarter Highlights
Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. Organic revenue for Cyteks existing product portfolio was $33.7 million in the first quarter of 2023, representing a decline of 4% compared to the... More